The identification of CMD is important because it carries an adverse prognosis [3–8] and directed treatment targeting endothelial dysfunction (e.g. external counterpulsation, HMG-CoA reductase inhibitors, ACEi) can improve the endothelial function. The gene discussed is HMGCR; the disease is endothelial dysfunction.